Bender et al. 2005: Long-Term Creatine Supplementation in Parkinson's Disease

TL;DR — Bender et al. 2005

Bender and colleagues published a study in Nutrition Research (2005) examining the long-term safety of creatine supplementation in patients with Parkinson’s disease. Over a 2-year period, 60 patients received either 4 g/day of creatine monohydrate or placebo alongside resistance training. The study confirmed that creatine was safe, with no adverse effects on kidney or liver function (A et al., 2005) . Functional benefits from combining creatine with exercise were also observed.

Background

Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons, mitochondrial dysfunction, and oxidative stress. Creatine’s role in cellular energy metabolism and its potential neuroprotective properties made it a candidate intervention.

Previous preclinical work, including Sullivan et al. (2000), had shown that creatine supplementation could protect against brain injury through mitochondrial support (PG et al., 2000) . Bender et al. sought to determine whether long-term creatine supplementation was safe and potentially beneficial in Parkinson’s patients.

Study Design

This was a randomized controlled trial with:

• Participants: 60 patients with diagnosed Parkinson’s disease
• Intervention: 4 g/day creatine monohydrate or placebo
• Duration: 2 years
• Monitoring: Regular blood tests for renal and hepatic function markers
• Additional intervention: Both groups participated in resistance training

Key Findings

1. Safety confirmed over 2 years

No adverse effects on renal function (creatinine clearance, BUN) or hepatic function (liver enzymes, bilirubin) were detected at any point during the 2-year study. This extended the safety evidence from healthy populations to a clinical neurological population.

2. Functional benefits observed

Participants receiving creatine combined with resistance training showed improvements in functional capacity compared to placebo. While the study was not powered to detect disease modification, the functional benefits were clinically meaningful.

3. Well tolerated

No participants withdrew from the study due to creatine-related side effects. Gastrointestinal tolerance was comparable between creatine and placebo groups.

Practical Implications

1. Creatine is safe in neurological populations: This study extends the safety evidence beyond healthy athletes to patients with neurodegenerative disease
2. Exercise plus creatine may benefit Parkinson’s patients: Combining resistance training with creatine supplementation appears to provide functional improvements
3. Standard maintenance dosing works: 4 g/day is within the ISSN-recommended range and was well tolerated (RB et al., 2017)
4. Long-term use is feasible: Two years of continuous supplementation produced no safety concerns

Malaysian Relevance

Parkinson’s disease affects approximately 20,000 Malaysians, with prevalence increasing as the population ages. The safety data from this study supports the consideration of creatine as a complementary intervention alongside standard Parkinson’s medications and physical therapy programs.

Limitations

• Moderate sample size of 60 participants
• Not designed to detect disease modification or progression changes
• Single-center study
• Creatine form limited to monohydrate at one dose level

Full Citation

Bender A, Koch W, Elstner M, et al. Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutrition Research. 2005;25(1):73-84. doi:10.1016/j.nutres.2005.09.003

Study Design and Methodology

Understanding how a study was designed helps assess the strength of its conclusions. Key methodological factors to evaluate include:

• Sample size — larger studies (n=50+) provide more reliable results than small studies (n=10-15). Small sample sizes increase the risk of false positives and limit the ability to detect moderate effect sizes
• Study duration — creatine research requires adequate duration for muscle saturation (minimum 4 weeks for maintenance dosing, 1 week for loading). Studies shorter than this may miss the full effect
• Blinding — double-blind, placebo-controlled designs (where neither researchers nor participants know who receives creatine) are the gold standard for minimising bias
• Population studied — results from trained athletes may not fully apply to untrained individuals, and vice versa. Age, sex, and dietary habits (particularly vegetarian status) also influence creatine response
• Outcome measures — direct measures (muscle biopsy, MRS imaging) are more informative than indirect proxies (blood markers, performance tests) for assessing creatine uptake and metabolism

Clinical Implications and Practical Relevance

This research contributes to our understanding of creatine in several practical ways:

For athletes and fitness enthusiasts: The findings support the use of creatine monohydrate as a safe, effective ergogenic aid. The standard dosing protocol of 3-5g daily remains well-supported by the cumulative evidence base including this study.

For healthcare professionals: Understanding the specific mechanisms and safety data from studies like this helps clinicians provide evidence-based guidance to patients who ask about creatine supplementation. The research consistently shows a favourable safety profile at recommended doses.

For the Malaysian context: While most creatine research is conducted in Western populations, the fundamental biochemistry (ATP-phosphocreatine system) is universal. Malaysian consumers can apply these findings with confidence, adjusting for local factors like tropical climate (increased hydration needs) and halal dietary requirements (synthetic creatine monohydrate is permissible).

How This Fits Into the Broader Evidence

No single study should be used to make definitive claims about creatine supplementation. Instead, this research should be viewed as one piece of a much larger evidence base:

• The ISSN Position Stand (2017) synthesises hundreds of studies into comprehensive recommendations
• Multiple systematic reviews and meta-analyses confirm creatine’s effects on strength, power, and lean mass
• Long-term safety data spanning up to 5 years shows no adverse effects at recommended doses

For a complete overview of the evidence, explore our Research Library which covers 60+ landmark creatine studies.

Sources & References

This article is based on the clinical trial by Bender et al. published in Nutrition Research (2005) and contextualized with Sullivan et al. (2000) and Kreider et al. (2017). All citations reference PubMed-indexed publications.

Further Reading

• creatine dosage guide
• creatine safety profile
• creatine monohydrate
• creatine for muscle building
• creatine for brain health
• how creatine works